ClinicalTrials.gg
CompletedNCT02534753Updated Mar 23, 2016

A Pharmacokinetics Study of Intravenous Ascorbic Acid

A Phase 1 interventional study of Ascor L 500® (Ascorbic Acid Injection, USP) in Pharmacokinetics, sponsored by McGuff Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-23.

Sponsored by McGuff Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.

Read the detailed description

The objectives of this study are:

  1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV).
  2. To evaluate the safety and tolerability of AA administered intravenously.
02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

This is the only study on the registry with McGuff Pharmaceuticals, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is between the ages of 18 and 45 years, inclusive.
  • Has a (BMI) between 18 and 32 kg/m2.
  • Of sound health and has the ability to understand the requirements of the study and is willing to comply with all study requirements and procedures.

Exclusion criteria

Exclusion Criteria:

  • Participates in activities that would not allow accurate evaluation of the pharmacokinetics of Ascorbic Acid
  • Medical or physical conditions that would not allow safe participation and/or accurate evaluation of the pharmacokinetics of Ascorbic Acid
  • Has participated in an drug study within the 30 days prior to CRU admission.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Single Group

    Drug: Ascor L 500® (Ascorbic Acid Injection, USP)

Interventions

06

What researchers measure

Primary outcomes

  1. Concentration of Ascorbic Acid (µM) in plasma

    Time frame: 1 day

Secondary outcomes

  1. Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) grouped by body system

    Time frame: 1 day

  2. Changes from Baseline in clinical laboratory and vital signs to discharge

    Time frame: 1 day

  3. Changes from pre-dose physical exam findings to discharge

    Time frame: 1 day

07

Study locations

1 site
  • Virginia Commonwealth University
    Richmond, Virginia 23284, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Nov 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2015
First posted
Aug 28, 2015
Start
Sep 2015
Primary completionActual
Nov 2015
CompletionActual
Jan 2016
Last update
Mar 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02534753
Lead sponsor
McGuff Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 28, 2015
Start date
Sep 2015
Primary completion
Nov 2015
Completion
Jan 2016
Last update
Mar 23, 2016

Study contacts

Damon P Jones, BS/MBA
study director · McGuff Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion